A global panel of experts discusses several recent data updates on the role of immunotherapy in non-small cell lung cancer (NSCLC) and their impact on clinical practice.
EP. 1: Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
September 28th 2022Melissa Johnson, MD, and Solange Peters, MD, review the available treatment options for stage I – III non-small cell lung cancer (NSCLC) and how the ESMO guidelines of patient management differ from the NCCN guidelines.
EP. 18: Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?
December 9th 2022Expert oncologists Melissa Johnson, MD, and Joshua Sabari, MD, discuss the occurrence of individual KRAS, STK11, or KEAP1 mutations in patients with non–small cell lung cancer and if there is a role for immunotherapy in the treatment of these patients.
EP. 20: Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations
December 16th 2022Contextualizing treatment selection with the POSEIDEN and CheckMate 9LA clinical trials, experts consider how to select the optimal treatment for patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated NSCLC.
EP. 22: Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations
December 23rd 2022Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.